Ivermectin

Ivermectin is a broad-spectrum antiparasitic medication belonging to the macrocyclic lactone drug class, derived from fermentation products of the soil microorganism Streptomyces avermitilis. This medication has become one of the most widely used antiparasitics in veterinary medicine due to its excellent efficacy against a wide range of internal and external parasites. In cats, ivermectin is used to treat various mite infestations including ear mites, sarcoptic mange, and demodicosis, as well as for heartworm prevention and control of certain intestinal parasites. While no ivermectin products are FDA-approved specifically for cats, the drug is extensively used in feline medicine based on established efficacy and safety data from decades of clinical experience.

The mechanism of action of ivermectin involves selective binding to glutamate-gated chloride channels in the nerve and muscle cells of invertebrate parasites. This binding causes increased permeability of the cell membrane to chloride ions, leading to hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite. Ivermectin demonstrates high selectivity for invertebrate chloride channels over mammalian receptors, which accounts for its favorable safety margin in most animals. The drug is distributed throughout body tissues after administration and reaches parasites through their blood meal or direct contact with treated tissues, providing both systemic and contact activity depending on the route of administration.

Ivermectin is available in multiple formulations suitable for feline use, though appropriate product selection and dosing require veterinary guidance. Injectable formulations can be given subcutaneously and provide prolonged drug levels useful for treating resistant mite infestations. Oral formulations, including tablets and liquids compounded for small animal use, offer convenient home administration for owners. Topical products containing ivermectin in combination with other active ingredients are available for cats, providing convenient monthly application for parasite prevention. The appropriate formulation depends on the condition being treated, the cat's tolerance of different administration routes, and veterinary recommendations.

The safety profile of ivermectin in cats is generally favorable when the medication is used at appropriate doses under veterinary supervision. However, the drug does carry risks of toxicity, particularly at higher doses or in certain sensitive individuals. Cats should never receive ivermectin products formulated for large animals such as horses or cattle, as these concentrated products can easily cause fatal overdose. Veterinary guidance is essential for determining appropriate dosing, monitoring for adverse effects, and ensuring that ivermectin is the most appropriate treatment choice for the individual patient's parasitic condition.

The primary indication for ivermectin in cats involves treatment of various mite infestations that cause significant discomfort and skin disease. Ear mites (Otodectes cynotis) are extremely common in cats, particularly kittens and cats from shelters or multi-cat environments, causing intense itching, head shaking, and dark waxy discharge from the ear canals. Ivermectin is highly effective against ear mites and can be administered via injection, orally, or applied topically depending on product formulation and veterinary preference. Treatment typically eliminates mite populations rapidly, though concurrent treatment of all cats in the household and environmental management may be necessary to prevent reinfestation.

Sarcoptic mange, caused by the burrowing mite Sarcoptes scabiei, is another important indication for ivermectin in cats. While less common in cats than dogs, sarcoptic mange causes intense pruritus, hair loss, and crusting skin lesions that can significantly impact quality of life. Ivermectin reaches mites burrowed within the skin after systemic administration, making it particularly effective for this condition. Treatment typically requires multiple doses given at intervals to eliminate mites at different life stages. Notoedric mange, caused by Notoedres cati and often called feline scabies, responds well to ivermectin therapy and represents a condition where this drug is often considered first-line treatment.

Feline demodicosis, caused by Demodex cati, Demodex gatoi, or occasionally other Demodex species, can be effectively treated with ivermectin, though treatment protocols vary depending on the specific species involved and extent of infestation. Demodex gatoi is particularly challenging because it is contagious between cats, unlike the more species-specific D. cati. Ivermectin protocols for demodicosis often require extended treatment courses with careful monitoring, as these mites can be difficult to eliminate completely. Veterinary supervision is essential for managing feline demodicosis, including proper diagnosis through skin scrapings and monitoring treatment response.

Beyond mite treatment, ivermectin serves as a heartworm preventive in cats, protecting against infection with Dirofilaria immitis transmitted by mosquitoes. Feline heartworm disease, while less common than canine heartworm disease, can be serious and even fatal, with no safe treatment available for adult heartworms in cats. Monthly ivermectin-based prevention kills heartworm larvae before they mature into adult worms. Ivermectin also provides activity against certain intestinal parasites including roundworms (Toxocara cati) and hookworms (Ancylostoma species), contributing to overall parasite control.

Veterinarians select ivermectin for feline patients based on the specific parasites present, the severity of infestation, and individual patient factors. For mite infestations, ivermectin offers advantages of systemic distribution and proven efficacy against multiple species. The availability of different formulations provides flexibility in administration approach. Cost-effectiveness compared to some newer products makes ivermectin attractive for shelter medicine and resource-limited situations. However, the need for accurate dosing and monitoring means that veterinary supervision is essential for safe and effective use.

The dosing protocol for ivermectin in cats requires careful attention because appropriate doses vary significantly depending on the condition being treated and the specific product formulation used. Veterinary supervision is essential for determining the correct dose for each individual patient, as overdosing can cause significant toxicity while underdosing may result in treatment failure. The general approach involves weight-based dosing using products of appropriate concentration, but the exact protocol depends on whether the drug is used for heartworm prevention, mite treatment, or other indications. Cat owners should never attempt to calculate doses from large animal ivermectin products, as the concentrated formulations designed for horses and cattle pose extreme overdose risk.

For heartworm prevention, ivermectin is typically used at doses of 24 micrograms per kilogram of body weight (0.024 mg/kg) administered orally once monthly. This preventive dose is well tolerated by cats and provides protection against heartworm larvae. Several commercial products incorporate ivermectin at this dose level in convenient formulations for cats. For intestinal parasite control, slightly higher doses may be used, though specific protocols should be determined by the prescribing veterinarian. Monthly administration during mosquito season, or year-round in endemic areas, provides continuous heartworm protection.

Treatment of mite infestations typically requires higher ivermectin doses than those used for heartworm prevention, administered on specific schedules that depend on the mite species involved. For ear mites, protocols may involve injectable ivermectin given subcutaneously at two-week intervals for two to three treatments, or daily oral administration for shorter periods. Sarcoptic and notoedric mange treatment usually involves subcutaneous injections given weekly for four to six weeks or until skin scrapings are negative for mites. Demodicosis may require even longer treatment courses with monitoring to ensure complete mite elimination. The veterinarian determines the specific protocol based on the type and severity of infestation.

Administration techniques vary by product formulation. Subcutaneous injections should be given using proper technique to ensure accurate dosing and minimize injection site reactions. Oral formulations should be given with or without food as directed by the specific product labeling; some cats tolerate oral medication better with a small amount of food. Topical formulations should be applied to the skin at the base of the neck where the cat cannot groom the product off. The application site should be parted to the skin and the entire dose applied in one spot. Following application, cats should not be bathed for at least 24 hours to allow complete absorption.

If a dose is missed during a treatment series, the situation should be discussed with the prescribing veterinarian to determine the appropriate action. For monthly heartworm prevention, a missed dose should be given as soon as remembered, then the schedule resumed. For mite treatment protocols involving multiple doses, extending the treatment course may be necessary to ensure complete parasite elimination. Never double doses to make up for missed treatments, as this increases toxicity risk without providing additional benefit.

Completing the full prescribed treatment course is essential for successful parasite elimination, particularly for mite infestations. Stopping treatment prematurely can allow surviving mites to repopulate, resulting in treatment failure and ongoing disease. For heartworm prevention, consistent monthly administration throughout the risk period is essential for maintaining protection. Cat owners should maintain regular veterinary appointments during treatment courses to assess response and adjust protocols as needed.

Ivermectin is generally well tolerated by cats when used at appropriate doses under veterinary supervision. The majority of cats receiving properly dosed ivermectin for heartworm prevention or mite treatment experience no adverse effects. However, as with any medication, side effects can occur, and cat owners should be aware of what reactions to monitor for during treatment. Understanding the difference between mild, expected effects and signs of toxicity requiring veterinary attention helps ensure prompt intervention when needed.

Mild side effects that may occur with ivermectin administration in cats include transient gastrointestinal upset such as drooling, vomiting, or decreased appetite. These effects are most commonly seen with oral administration and typically resolve within 24 hours without specific treatment. Some cats may show mild lethargy or reduced activity for a day after treatment. Injection site reactions, including temporary swelling, discomfort, or hair loss at the injection site, can occur with subcutaneous administration but are usually mild and self-limiting. These common side effects generally do not require treatment discontinuation.

Moderate side effects warranting veterinary contact include persistent vomiting or diarrhea lasting more than 24 hours, significant appetite loss, or noticeable behavioral changes. Cats showing signs of disorientation, vision changes, or altered gait should be evaluated promptly. Some cats may experience mydriasis (dilated pupils) as an early sign of neurological effects. Skin reactions including localized or generalized itching not attributable to the underlying parasitic condition should be reported to the veterinarian. These moderate effects may indicate individual sensitivity or dosing issues that require protocol adjustment.

Serious ivermectin toxicity in cats, while uncommon at appropriate doses, represents a veterinary emergency requiring immediate attention. Signs of severe toxicity include profound depression or stupor, tremors, ataxia (loss of coordination), blindness, excessive salivation, seizures, and coma. These neurological signs result from ivermectin crossing the blood-brain barrier and affecting central nervous system function. Toxicity is most commonly seen with accidental overdose, particularly from exposure to concentrated large animal formulations. Cats showing any neurological abnormalities after ivermectin administration should receive immediate veterinary care.

Rare idiosyncratic reactions can occur in individual cats regardless of dose, though these are difficult to predict. Some cats appear to have increased sensitivity to ivermectin that may be related to genetic factors affecting drug transport across the blood-brain barrier. Long-term use concerns are minimal at standard preventive doses, but cats receiving extended high-dose treatment for mite infestations should be monitored throughout the treatment course. Cat owners should report any unexpected reactions to their veterinarian promptly, allowing for assessment of whether to continue treatment and consideration of alternative medications if indicated.

Ivermectin should not be administered to cats with known hypersensitivity or previous adverse reactions to ivermectin or other macrocyclic lactone drugs. While true allergic reactions to ivermectin are rare, any cat that has experienced neurological toxicity, severe gastrointestinal effects, or other significant adverse reactions following previous ivermectin administration should not receive the drug again. Cross-reactivity between different macrocyclic lactones (such as ivermectin, selamectin, and moxidectin) is possible, so caution should be exercised when considering alternative medications within this drug class for cats that reacted to one member.

Cats with certain genetic conditions affecting drug transport may be at increased risk of ivermectin toxicity. While the MDR1 gene mutation associated with ivermectin sensitivity is more thoroughly documented in dogs, particularly herding breeds, the possibility of similar individual variation in cats should be considered. The blood-brain barrier normally prevents ivermectin from reaching the central nervous system in significant concentrations, but dysfunction of drug efflux pumps can allow higher brain concentrations and neurological toxicity. Cats showing unexpected sensitivity to ivermectin at standard doses may have underlying transport protein variations.

Very young kittens require careful consideration before ivermectin administration, as their immature blood-brain barrier may allow greater drug penetration into the central nervous system compared to adult cats. Most ivermectin-containing products specify minimum ages for use, typically four to six weeks depending on the product. Kittens younger than the recommended minimum age should not receive ivermectin, and appropriate alternatives should be selected for parasite control in very young animals. The prescribing veterinarian should be informed of the exact age of kittens requiring treatment.

Pregnant and nursing cats represent populations where ivermectin use requires careful evaluation. While ivermectin has been used safely in pregnant cats at standard preventive doses, higher doses used for mite treatment may pose greater risk. The drug does cross the placenta and appears in milk, potentially affecting developing fetuses and nursing kittens. Veterinarians typically weigh the severity of parasitic disease against potential reproductive risks when making treatment decisions for pregnant or lactating queens. Cats with severe debilitation, dehydration, or concurrent serious illness may have altered drug distribution and metabolism that affects ivermectin safety. Complete health assessment before treatment initiation helps identify cats that may require dose adjustments or alternative medications.

Prior to initiating ivermectin therapy, cat owners should provide their veterinarian with a complete list of all medications, supplements, and products their cat receives. Drug interactions can alter ivermectin's effectiveness or increase toxicity risk, making comprehensive medication review essential for safe treatment. While ivermectin has relatively few documented interactions in cats compared to some other medications, the potential for interactions exists and should be evaluated for each patient.

The most clinically significant drug interactions with ivermectin involve medications that affect P-glycoprotein (P-gp) or other drug transport proteins. P-glycoprotein functions to pump ivermectin out of the central nervous system, preventing toxic accumulation. Drugs that inhibit P-glycoprotein can increase brain ivermectin concentrations, potentially causing neurological toxicity even at standard doses. Medications that may inhibit P-glycoprotein and could interact with ivermectin include certain antifungals (ketoconazole, itraconazole), some antibiotics (erythromycin), cardiac medications (amiodarone), and others. Veterinarians should review all concurrent medications for potential P-glycoprotein interactions.

Concurrent use of ivermectin with other antiparasitic medications should be carefully evaluated. While combination protocols may sometimes be appropriate for treating complex parasitic infections, additive effects on the nervous system or other organ systems could increase toxicity risk. Other macrocyclic lactones (selamectin, moxidectin) should not typically be used simultaneously with ivermectin due to overlapping mechanisms of action. When switching between antiparasitic products, appropriate washout periods should be observed. The veterinarian can advise on safe timing and combinations for each patient's specific situation.

Dietary factors and supplements generally have minimal impact on ivermectin efficacy, but any products the cat receives should be disclosed to the veterinarian. Certain herbal supplements may affect liver enzyme activity or drug transport proteins, potentially influencing ivermectin metabolism. Administering oral ivermectin with food versus on an empty stomach can affect absorption of some formulations. Following specific product instructions or veterinary recommendations regarding administration with food optimizes consistent drug levels. Cat owners should watch for signs of potential drug interactions, including unexpected sedation, neurological changes, or lack of expected treatment response, and report any concerns promptly.

Standard precautions for ivermectin use in cats emphasize the critical importance of accurate dosing and veterinary supervision. Cat owners should never attempt to calculate ivermectin doses from products formulated for large animals such as horses or cattle, as these concentrated formulations are extremely dangerous for cats. Even small errors in measuring such concentrated products can result in massive overdose and potentially fatal toxicity. Only products specifically formulated for cats or diluted and calculated by a veterinarian should be used. Weight measurement should be accurate and current, as dose calculations based on estimated or outdated weights may result in under- or overdosing.

Breed-specific concerns with ivermectin in cats are less clearly defined than in dogs, where certain herding breeds have well-documented sensitivity. However, individual cats of any breed may show unexpected sensitivity to ivermectin. Cats that have never received ivermectin before should be monitored carefully after the first dose for any signs of adverse reaction. Starting with lower doses when high-dose protocols are planned (such as for mite treatment) and gradually increasing may help identify sensitive individuals before serious toxicity occurs. Any cat showing neurological signs after ivermectin administration should not receive additional doses until evaluated by a veterinarian.

Handling and storage precautions protect both the cat and household members. Ivermectin products should be stored securely out of reach of children and pets. Accidental ingestion of ivermectin by children can cause significant toxicity and requires immediate medical attention. Cat owners should wash hands after administering the medication. Injectable formulations require proper handling technique and disposal of used needles in sharps containers. Environmental contamination should be minimized by following product instructions for application and disposal.

Monitoring during treatment involves observing for both therapeutic efficacy and adverse effects. For mite infestations, improvement in clinical signs such as reduced itching, healing of skin lesions, and resolution of ear discharge indicates treatment success. Skin scrapings or ear cytology may be performed periodically to confirm mite elimination. Watch for any signs of toxicity including behavioral changes, coordination problems, or neurological abnormalities. Report any concerns to the veterinarian promptly, as early intervention can prevent progression of toxicity.

Special populations require additional precautions. Geriatric cats may have altered drug metabolism and elimination that affects ivermectin handling. Cats with hepatic or renal dysfunction should be carefully evaluated before treatment, as impaired organ function can affect drug clearance. Debilitated or severely ill cats may be more susceptible to adverse effects. Cats receiving immunosuppressive therapy may have altered responses to parasitic infections and potentially different medication tolerance. Comprehensive health assessment before initiating ivermectin therapy helps identify cats requiring modified protocols or alternative treatments.

Ivermectin products should be stored according to their specific labeling requirements, which vary by formulation. Most oral and injectable formulations are stored at controlled room temperature between 68°F and 77°F (20°C to 25°C), protected from light and excessive heat or cold. Some liquid formulations may require refrigeration after opening; cat owners should check product labeling for specific requirements. Storage location should maintain consistent conditions away from direct sunlight, heating vents, or areas subject to temperature extremes. Original packaging provides light protection and should be retained until the product is used.

Formulation-specific storage considerations apply to different ivermectin product types. Injectable solutions should remain in their original vials with proper closure between uses. Multi-dose vials should be inspected before each use for any changes in color, clarity, or presence of particles that might indicate contamination or degradation. Oral tablets should remain in blister packs or bottles until use to protect from moisture. Compounded formulations may have different stability characteristics than manufactured products; follow the compounding pharmacy's specific storage instructions and note any beyond-use dates. Topical products should be stored with applicators sealed until immediately before use.

Expiration dates should be checked before administering any ivermectin product, as expired medications may have reduced potency or altered safety profiles. Using expired antiparasitic medications risks treatment failure due to inadequate drug levels and should be avoided. Products approaching expiration should be replaced with fresh supplies rather than used past their dates. For ongoing heartworm prevention programs, cat owners should plan refills to maintain supplies of in-date medication.

Safe handling and disposal practices protect household members, pets, and the environment. Ivermectin products should be stored in locations inaccessible to children and pets, as accidental ingestion can cause serious toxicity. When handling the medication, avoid direct skin contact with concentrated formulations; wearing gloves during administration of injectable products is advisable. Wash hands thoroughly after any contact with ivermectin products. Used needles and syringes should be disposed of in appropriate sharps containers. Unused medication should not be discarded in household trash or flushed down drains; veterinary clinics and many pharmacies offer medication disposal programs that ensure safe handling of pharmaceutical waste.

Most cat breeds tolerate ivermectin well at appropriate doses, as the species-wide safety profile of this medication in cats is generally favorable when used under veterinary supervision. Unlike dogs, where specific herding breeds have well-documented genetic sensitivity to ivermectin due to MDR1 gene mutations, comparable breed-specific sensitivities in cats have not been clearly established. However, this does not eliminate the possibility of individual variation, and cats of any breed may show unexpected reactions to ivermectin. Careful monitoring during initial doses remains important regardless of breed.

While breed-specific ivermectin sensitivities in cats are not well documented, certain observations suggest possible variation. Some anecdotal reports have suggested increased sensitivity in certain white-coated cats, though this has not been systematically confirmed. Oriental breeds and related cats may have different drug metabolism characteristics, though clinical significance for ivermectin specifically is unclear. The important principle is that any individual cat, regardless of breed, could potentially show sensitivity to ivermectin, making careful dosing and monitoring essential for all patients.

Size variation among cat breeds affects practical dosing considerations. Large breeds such as Maine Coons, Ragdolls, and Norwegian Forest Cats may require larger total doses based on their greater body weight. Accurate weighing is particularly important for these larger cats to ensure adequate dosing without excessive drug exposure. Conversely, small breeds and naturally petite cats require precise dosing to avoid relative overdose. Toy-sized cats present particular challenges for accurate dose measurement, and concentration of the product used becomes important. Veterinarians may select specific formulations or compounded preparations to allow accurate dosing across the range of feline sizes.

Age-related factors apply across all breeds when considering ivermectin use. Kittens have immature blood-brain barriers that may allow greater central nervous system drug penetration, increasing toxicity risk at standard doses. Most products specify minimum ages for use, typically around four to six weeks. Senior cats may have age-related changes in liver and kidney function affecting drug metabolism and clearance, potentially requiring dose adjustments. Cats with chronic diseases common in certain breeds (such as hypertrophic cardiomyopathy in Maine Coons or polycystic kidney disease in Persians) should have these conditions considered when planning antiparasitic treatment. Veterinary guidance ensures appropriate ivermectin use regardless of breed or age.

Within the macrocyclic lactone drug class, several alternatives to ivermectin offer similar antiparasitic activity with potentially different convenience profiles or safety characteristics. Selamectin (Revolution, Revolution Plus) is a macrocyclic lactone formulated as a topical solution specifically for cats, providing monthly protection against fleas, heartworms, ear mites, and intestinal parasites. Moxidectin, available in combination products such as Advantage Multi, offers another macrocyclic lactone option with activity against heartworms and various mites. Milbemycin oxime, found in some combination heartworm preventives, provides yet another macrocyclic lactone choice. These alternatives may be preferred when topical administration is more convenient than injectable or oral ivermectin, or when different parasite coverage is desired.

Alternative drug classes for treating mites and mange in cats include the isoxazoline ectoparasiticides and lime sulfur. Isoxazolines such as sarolaner (in Revolution Plus), fluralaner (Bravecto), and lotilaner (Credelio Cat) provide excellent efficacy against fleas and ticks with some activity against certain mites. These newer drugs work through different mechanisms than ivermectin and may be appropriate alternatives when ivermectin is not suitable. Lime sulfur dip represents a traditional treatment for mites and dermatophytosis (ringworm) that works through direct contact activity rather than systemic distribution. While requiring more intensive application than systemic medications, lime sulfur has an excellent safety profile and remains valuable for certain patients.

Complementary approaches enhance antiparasitic treatment effectiveness and prevent reinfestation. For ear mite treatment, topical ear cleaning and medications may supplement systemic ivermectin therapy. Environmental management including thorough cleaning and treatment of bedding helps eliminate mite reservoirs. In multi-cat households, treating all cats simultaneously prevents ongoing transmission of contagious mites like Demodex gatoi. Immune support through proper nutrition and stress reduction may help cats clear parasitic infections more effectively. Veterinary guidance is essential when selecting among available antiparasitic options, as the choice depends on the specific parasites involved, individual patient factors, and practical considerations for administration. Cat owners should never substitute medications without professional consultation.